Fig. 2From: Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil countsBenralizumab pre-therapy and post-therapy serum eosinophil count, cells/μLBack to article page